- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
Patent holdings for IPC class C07D 417/12
Total number of patents in this class: 7012
10-year publication summary
|
514
|
462
|
529
|
495
|
504
|
414
|
431
|
491
|
405
|
214
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Bristol-myers Squibb Company | 4875 |
181 |
| Merck Sharp & Dohme LLC | 3749 |
106 |
| Novartis AG | 10856 |
101 |
| Boehringer Ingelheim International GmbH | 4665 |
98 |
| F. Hoffmann-La Roche AG | 7930 |
97 |
| BASF SE | 20912 |
96 |
| AstraZeneca AB | 2923 |
76 |
| Janssen Pharmaceutica N.V. | 3392 |
69 |
| Takeda Pharmaceutical Company Limited | 2714 |
65 |
| Shionogi & Co., Ltd. | 860 |
65 |
| Amgen Inc. | 4073 |
64 |
| Vertex Pharmaceuticals Incorporated | 1599 |
60 |
| Bayer Cropscience AG | 2042 |
54 |
| Hoffmann-La Roche Inc. | 3408 |
53 |
| Syngenta Participations AG | 1906 |
52 |
| The Regents of the University of California | 19887 |
50 |
| Gilead Sciences, Inc. | 2036 |
48 |
| Abbvie Inc. | 1805 |
45 |
| Bayer AG | 3332 |
42 |
| Allergan, Inc. | 2350 |
39 |
| Other owners | 5551 |